Observational findings confirm improved overall survival with durvalumab plus gemcitabine in advanced biliary tract cancer, suggesting significant clinical benefits.
Background: In the TOPAZ-1 study (NCT03875235), durvalumab combined with gemcitabine and cisplatin (D+GC) significantly improved overall survival (OS) in advanced biliary tract cancer patients compared to placebo with GC (P+GC). Updated results show a meaningful 3-year OS benefit for D+GC.
No takes yet. Share an insight, caveat, or question.
Pelzer et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: